Larimar Therapeutics (LRMR) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 53.0% versus a loss of 44.0%. Over five years, LRMR leads with a -77.7% price change compared with -96.6% for ZNTL. Larimar Therapeutics is the larger company by market cap ($275.3 million vs $252.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | ZNTL |
|---|---|---|
| Share price | $2.65 | $2.58 |
| Market cap | $275.29M | $252.66M |
| 1-day change | -1.85% | +2.59% |
| YTD return | -29.13% | +85.93% |
| 1-year return | -43.98% | +53.05% |
| 5-year return | -77.72% | -96.60% |
| EPS (TTM) | $-1.99 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $6.95 |
| 52-week low | $2.61 | $1.21 |
| Distance from 52-week high | -58.72% | -62.95% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +443.40% | +184.66% |
| Average volume | 1.27M | 1.21M |
| Shares outstanding | 103.88M | 98.12M |
| Employees | 71 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed LRMR by 97.0 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
LRMR vs ZNTL FAQ
Which is bigger, Larimar Therapeutics or Zentalis Pharmaceuticals?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $275.29M compared with $252.66M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, LRMR or ZNTL?
ZNTL returned +53.05% over the past 12 months, compared with -43.98% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.